The manufacturing process for Strangvac, the new vaccine against equine strangles, is proceeding according to plan

The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice)

We are very pleased to announce that we have now manufactured the drug substances for several million doses of Strangvac, the new vaccine against equine strangles” says Andreas Andersson, CEO Intervacc AB

An important preparatory step has now been completed for the final completion of validation batches needed for submission of a registration application to the European Medicines Agency (EMA). This confirms the previously established timetable for Strangvac and that the process for large-scale manufacturing works well” says Jan-Ingmar Flock, Chief Scientific Officer at Intervacc.

The final steps in the manufacturing process for Strangvac are done in collaboration with Praxis Pharmaceuticals in Spain that provide final formulation, filling of vials and packaging of finished product.

Strangvac has undergone clinical trials and safety tests with good results. Intervacc intends to submit a registration application for Strangvac at the end of 2019.

To do this, two large-scale commercial batches in compliance with GMP must be manufactured, where the drug substances now have been manufactured at a level sufficient for several million doses, in addition to the validation batches required for the application.

The vaccine has been developed with a technology based on recombinant proteins instead of killed or attenuated micro-organisms, which is found in conventional vaccines. This reduces the risk of serious side effects – one of several good characteristics in a new generation of vaccines based on recombinant proteins.

Original source: Intervacc

Related Content

3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more

3P Biopharmaceuticals appoints Diego Bochoeyer as Director of Strategic Development and Supply Chain

3P Biopharmaceuticals incorporates a new member to the executive management team by engaging Diego Bochoeyer as Director of Strategic Development and Supply Chain.
Read more

3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology

3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.